Immunome (NASDAQ:IMNM) Announces Earnings Results

Immunome (NASDAQ:IMNM) released its quarterly earnings results on Tuesday. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.10), FiscalAI reports. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%.

Here are the key takeaways from Immunome’s conference call:

• Varegacestat delivered striking phase III topline results (84% reduction in progression risk, HR 0.16; 56% ORR; 83% median tumor volume reduction) and Immunome plans an NDA submission in Q2 2026 with a generally manageable safety profile and intent to self-launch.
• Company says previous manufacturing issues have been resolved, with ample commercial supply capacity and a planned cost‑effective U.S. launch infrastructure (roughly the ~32–35 rep footprint comparable to the prior launch).
• Immunome’s proprietary ADC payload HC74 (Topo1) claims resistance to efflux mechanisms and enhanced bystander activity; lead ADC IM‑1021 is in dose escalation and three additional HC74 ADCs (including IM‑1617 with a strong preclinical package) are expected to file INDs in 2026, materially expanding the pipeline.
• Significant execution and translational risk remains: ADCs and the FAP radiotherapy program are early‑stage (preclinical/phase I), and expanding the desmoid market beyond the ~10% currently on gamma‑secretase inhibitors will depend on real‑world adherence, payer uptake, and successful NDA review.

Immunome Stock Down 3.0%

NASDAQ IMNM opened at $21.54 on Wednesday. Immunome has a twelve month low of $5.15 and a twelve month high of $27.65. The stock has a market cap of $2.38 billion, a P/E ratio of -7.30 and a beta of 2.12. The company’s 50-day simple moving average is $22.78 and its 200 day simple moving average is $17.54.

Insiders Place Their Bets

In related news, CEO Clay B. Siegall acquired 46,511 shares of the firm’s stock in a transaction on Thursday, December 18th. The shares were bought at an average cost of $21.50 per share, with a total value of $999,986.50. Following the completion of the acquisition, the chief executive officer owned 853,247 shares of the company’s stock, valued at $18,344,810.50. This trade represents a 5.77% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Isaac Barchas sold 383,200 shares of the stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $21.74, for a total value of $8,330,768.00. Following the completion of the transaction, the director directly owned 2,031,181 shares of the company’s stock, valued at approximately $44,157,874.94. The trade was a 15.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders acquired a total of 68,518 shares of company stock worth $1,453,958 over the last quarter. Company insiders own 7.69% of the company’s stock.

Institutional Investors Weigh In On Immunome

Several institutional investors and hedge funds have recently made changes to their positions in IMNM. Stoneridge Investment Partners LLC increased its holdings in shares of Immunome by 5.4% in the third quarter. Stoneridge Investment Partners LLC now owns 12,174 shares of the company’s stock valued at $143,000 after purchasing an additional 620 shares in the last quarter. ANTIPODES PARTNERS Ltd boosted its position in Immunome by 6.1% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 10,892 shares of the company’s stock valued at $128,000 after buying an additional 631 shares during the last quarter. Creative Planning boosted its position in Immunome by 4.0% in the 3rd quarter. Creative Planning now owns 18,664 shares of the company’s stock valued at $219,000 after buying an additional 710 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Immunome by 14.4% in the 4th quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock valued at $159,000 after buying an additional 935 shares during the period. Finally, California State Teachers Retirement System increased its stake in shares of Immunome by 1.8% in the 4th quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock valued at $1,439,000 after buying an additional 1,167 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on IMNM shares. Lake Street Capital lifted their price target on Immunome from $22.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Leerink Partners set a $40.00 target price on shares of Immunome in a research report on Monday, December 15th. Truist Financial began coverage on shares of Immunome in a research note on Monday, December 1st. They set a “buy” rating and a $36.00 target price for the company. Guggenheim increased their price target on shares of Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Finally, Wedbush restated an “outperform” rating and set a $31.00 price objective on shares of Immunome in a report on Thursday, January 15th. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.50.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.